| Literature DB >> 36006162 |
Ana Tavares1, Kukka Aimonen2, Sophie Ndaw3, Aleksandra Fučić4, Julia Catalán2,5, Radu Corneliu Duca6,7, Lode Godderis6,8, Bruno C Gomes9, Beata Janasik10, Carina Ladeira11, Henriqueta Louro1,9, Sónia Namorado1, An Van Nieuwenhuyse6,7, Hannu Norppa2, Paul T J Scheepers12, Célia Ventura1,9, Jelle Verdonck6, Susana Viegas13,14, Wojciech Wasowicz10, Tiina Santonen2, Maria João Silva1,9.
Abstract
A study was conducted within the European Human Biomonitoring Initiative (HBM4EU) to characterize occupational exposure to Cr(VI). Herein we present the results of biomarkers of genotoxicity and oxidative stress, including micronucleus analysis in lymphocytes and reticulocytes, the comet assay in whole blood, and malondialdehyde and 8-oxo-2'-deoxyguanosine in urine. Workers from several Cr(VI)-related industrial activities and controls from industrial (within company) and non-industrial (outwith company) environments were included. The significantly increased genotoxicity (p = 0.03 for MN in lymphocytes and reticulocytes; p < 0.001 for comet assay data) and oxidative stress levels (p = 0.007 and p < 0.001 for MDA and 8-OHdG levels in pre-shift urine samples, respectively) that were detected in the exposed workers over the outwith company controls suggest that Cr(VI) exposure might still represent a health risk, particularly, for chrome painters and electrolytic bath platers, despite the low Cr exposure. The within-company controls displayed DNA and chromosomal damage levels that were comparable to those of the exposed group, highlighting the relevance of considering all industry workers as potentially exposed. The use of effect biomarkers proved their capacity to detect the early biological effects from low Cr(VI) exposure, and to contribute to identifying subgroups that are at higher risk. Overall, this study reinforces the need for further re-evaluation of the occupational exposure limit and better application of protection measures. However, it also raised some additional questions and unexplained inconsistencies that need follow-up studies to be clarified.Entities:
Keywords: 8-OHdG; MDA; biomonitoring; chromate; comet assay; effect biomarkers; micronuclei; occupational exposure
Year: 2022 PMID: 36006162 PMCID: PMC9412464 DOI: 10.3390/toxics10080483
Source DB: PubMed Journal: Toxics ISSN: 2305-6304
Participants’ distribution among the exposure groups (workers/controls) according to their main characteristics.
| Independent Variables | Participants with MN PBL Data | Participants with MN RET Data | Participants with Comet Assay Data | Participants with Oxidative stress Biomarkers Data | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Participants | Total Workers | Total Controls a | Total Participants | Total Workers | Total Controls a | Total Participants | Total Workers | Total Controls a | Total Participants | Total Workers | Total Controls a | |
|
| 284 | 191 (67.3) | 93 (32.7) | 256 | 170 (66.4) | 86 (33.6) | 117 | 74 (63.2) | 43 (36.8) | 299 | 215 (71.9) | 84 (28.1) |
|
| 284 | 256 | 117 | 299 | ||||||||
|
| 69 (24.3) | 48 (25.1) | 21 (22.6) | 69 (27.0) | 48 (28.2) | 21 (24.4) | 29 (24.8) | 16 (21.6) | 13 (30.2) | 67 (22.4) | 53 (24.7) | 14 (16.7) |
|
| 56 (19.7) | 33 (17.3) | 23 (24.7) | 61 (23.8) | 37 (21.8) | 24 (27.9) | 20 (17.1) | 14 (18.9) | 6 (14.0) | 72 (24.1) | 47 (21.9) | 25 (29.8) |
|
| 30 (10.6) | 20 (10.5) | 10 (10.8) | 30 (10.0) | 20 (9.3) | 10 (11.9) | ||||||
|
| 71 (25.0) | 52 (27.2) | 19 (20.4) | 69 (27.0) | 51 (30.0) | 18 (20.9) | 8 (6.8) | 5 (6.8) | 3 (7.0) | 71 (23.7) | 52 (24.2) | 19 (22.6) |
|
| 58 (20.4) | 38 (19.9) | 20 (21.5) | 57 (22.3) | 34 (20.0) | 23 (26.7) | 60 (51.3) | 39 (52.7) | 21 (48.8) | |||
|
| 59 (19.7) | 43 (20.0) | 16 (19.0) | |||||||||
|
| 284 | 256 | 117 | 299 | ||||||||
|
| 35 (12.3) | 7 (3.7) | 28 (30.1) | 30 (11.7) | 7 (4.1) | 23 (26.7) | 15 (12.8) | 5 (6.8) | 10 (23.3) | 32 (10.7) | 4 (1.9) | 28 (33.3) |
|
| 249 (87.7) | 184 (96.3) | 65 (69.9) | 226 (88.3) | 163 (95.9) | 63 (73.3) | 102 (87.2) | 69 (93.2) | 33 (76.7) | 267 (89.3) | 211 (98.1) | 56 (66.7) |
|
| ||||||||||||
|
| 42.0 | 41.1 | 43.6 | 41.9 | 41.1 | 43.5 | 43.5 | 42.8 | 44.6 | 41.7 | 41.1 | 43.4 |
|
| 10.4 | 11.0 | 8.88 | 10.5 | 11.1 | 9.28 | 9.94 | 11.0 | 7.89 | 10.5 | 10.6 | 9.88 |
|
| 20–68 | 20–68 | 23–63 | 20–68 | 20–68 | 23–63 | 20–64 | 20–64 | 30–60 | 20–68 | 20–68 | 23–63 |
|
| 274 | 246 | 110 | 293 | ||||||||
|
| 200 (73.0) | 132 (72.5) | 68 (73.9) | 179 (72.8) | 116 (72.0) | 63 (74.1) | 76 (69.1) | 47 (69.1) | 29 (69.0) | 217 (74.1) | 154 (73.3) | 63 (75.9) |
|
| 74 (27.0) | 50 (27.5) | 24 (26.1) | 67 (27.2) | 45 (28.0) | 22 (25.9) | 34 (30.9) | 21 (30.9) | 13 (31.0) | 76 (25.9) | 56 (26.7) | 20 (24.1) |
|
| 279 | 251 | 112 | 296 | ||||||||
|
| 78 (28.0) | 69 (36.9) | 12 (13.0) | 66 (26.3) | 55 (33.1) | 11 (12.9) | 29 (25.9) | 22 (31.4) | 7 (16.7) | 81 (27.4) | 72 (33.8) | 9 (10.8) |
|
| 35 (12.5) | 46 (24.6) | 13 (14.1) | 52 (20.7) | 41 (24.7) | 11 (12.9) | 24 (21.4) | 18 (25.7) | 6 (14.3) | 73 (24.7) | 59 (27.7) | 14 (16.9) |
|
| 166 (59.5) | 72 (38.5) | 67 (72.8) | 133 (53.0) | 70 (42.2) | 63 (74.1) | 59 (52.7) | 30 (42.9) | 29 (69.0) | 142 (48.0) | 82 (38.5) | 60 (72.3) |
|
| 279 | 251 | 112 | 296 | ||||||||
|
| 51 (18.3) | 34 (18.2) | 17 (18.5) | 45 (17.9) | 29 (17.5) | 16 (18.8) | 30 (26.8) | 21 (30.0) | 9 (21.4) | 40 (13.5) | 29 (13.6) | 11 (13.3) |
|
| 114 (40.9) | 79 (42.2) | 35 (38.0) | 116 (46.2) | 79 (47.6) | 37 (43.5) | 30 (26.8) | 13 (18.6) | 17 (40.5) | 128 (43.2) | 94 (44.1) | 34 (41.0) |
|
| 114 (40.9) | 74 (36.9) | 40 (43.5) | 90 (35.9) | 58 (34.9) | 32 (37.6) | 52 (46.4) | 36 (51.4) | 16 (38.1) | 128 (43.2) | 90 (42.3) | 38 (45.8) |
|
| 279 | 251 | 112 | 293 | ||||||||
|
| 199 (71.3) | 130 (69.5) | 69 (75.0) | 175 (69.7) | 113 (68.1) | 62 (72.9) | 84 (75.0) | 55 (78.6) | 29 (69.0) | 187 (63.8) | 127 (60.2) | 60 (73.2) |
|
| 80 (28.7) | 57 (30.5) | 23 (25.0) | 76 (30.3) | 53 (31.9) | 23 (27.1) | 28 (25.0) | 15 (21.4) | 13 (31.0) | 106 (36.2) | 84 (39.8) | 22 (26.8) |
|
| 275 | 247 | 112 | 294 | ||||||||
|
| 206 (74.9) | 134 (73.2) | 72 (78.3) | 183 (74.1) | 116 (71.6) | 67 (78.8) | 89 (79.5) | 54 (77.1) | 35 (83.3) | 207 (70.4) | 152 (72.0) | 55 (66.3) |
|
| 69 (25.1) | 49 (26.8) | 20 (21.7) | 64 (25.9) | 46 (28.4) | 18 (21.2) | 23 (20.5) | 16 (22.9) | 7 (16.7) | 87 (29.6) | 59 (28.0) | 28 (33.7) |
|
| 279 | 251 | 109 | 296 | ||||||||
|
| 139 (49.8) | 96 (51.3) | 43 (46.7) | 119 (47.4) | 82 (49.4) | 37 (43.5) | 59 (52.7) | 37 (52.9) | 22 (52.4) | 160 (54.1) | 119 (55.9) | 41 (49.4) |
|
| 113 (40.5) | 70 (37.4) | 43 (46.7) | 108 (43.0) | 66 (39.8) | 42 (49.4) | 42 (37.5) | 25 (35.7) | 17 (40.5) | 103 (34.8) | 68 (31.9) | 35 (42.2) |
|
| 27 (9.7) | 21 (11.2) | 6 (6.5) | 24 (9.6) | 18 (10.8) | 6 (7.1) | 11 (9.8) | 8 (11.4) | 3 (7.1) | 33 (11.1) | 26 (12.2) | 7 (8.4) |
a Total controls include participants that were recruited within the company and outwith the company; MN: micronuclei; PBL: peripheral blood lymphocytes; RET: reticulocytes.
Figure 1Mean (±SD) urinary total chromium levels in post-shift urine samples per exposure activity and control groups that were assessed for each of the different effect biomarkers.
Results of genotoxicity biomarkers that were analyzed in the blood cells from workers that were exposed to Cr(VI) and the control groups (mean ± SD).
| MN PBL | MN RET | Comet Assay | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | MNBC (‰) | MN in BC (‰) | NPB (‰) | NBUD (‰) | CBPI | n | Micronucleated +CD71 Reticulocytes | n | Tail Intensity | |
|
|
|
|
|
|
|
|
|
|
|
|
| Bath plating workers | 39 | 12.56 ± 8.04 £ | 14.32 ± 9.64 £ | 3.02 ± 3.56 £ | 0.65 ± 0.98 £ | 1.72 ± 0.33 * | 19 | 1.88 ± 1.14 * | 12 | 7.36 ± 1.61 £ ¥ |
| Chromate paint applicators | 34 | 9.72 ± 6.36 £ | 10.82 ± 7.07 £ | 1.65 ± 2.98 | 0.40 ± 0.74 * ¥ | 1.83 ± 0.24 | 33 | 2.03 ± 1.11 * | 25 | 5.24 ± 1.26 * £ |
| Welders | 87 | 7.37 ± 4.78 * ¥ | 8.55 ± 5.79 * ¥ | 1.51 ± 2.89 £ | 0.60 ± 1.08 * | 1.86 ± 0.23 £ | 90 | 3.40 ± 2.25 £ ¥ | 19 | 7.62 ± 1.92 £ ¥ |
| Machining workers | 12 | 8.04 ± 3.09 | 9.62 ± 4.01 | 0.63 ± 0.91 £ | 0.79 ± 0.99 * ¥ | 2.00 ± 0.23 £ | 10 | 2.30 ± 1.34 | 5 | 5.04 ± 2.03 £ |
| Other activities | 19 | 9.60 ± 4.76 £ | 11.27 ± 5.97 £ | 1.17 ± 1.21 | 0.39 ± 0.74 | 1.98 ± 0.14 £ | 18 | 1.97 ± 0.72 | 13 | 6.12 ± 1.04 * £ |
|
|
|
|
|
|
|
|
|
|
|
|
| Within company | 60 | 12.19 ± 7.58 £ | 13.68 ± 8.40 £ | 2.03 ± 2.36 £ | 0.65 ± 0.97 £ | 1.88 ± 0.30 £ | 50 | 3.13 ± 2.67 £ | 24 | 6.88 ± 2.44 £ |
| Outwith company | 33 | 7.33 ± 5.47 * | 8.61 ± 6.77* | 1.29 ± 2.30 * | 0.18 ± 0.41 * | 1.74 ± 0.24 * | 36 | 1.92 ± 0.68 * | 19 | 1.71 ± 1.18 * |
MN PBL—cytokinesis-block micronucleus assay in peripheral blood lymphocytes; MNBC—frequency of micronucleated binucleated cells per 1000 binucleated cells; MN—micronuclei per 1000 binucleated cells; NPB—nucleoplasmic bridges per 1000 binucleated cells; NBUD—nuclear buds per 1000 binucleated cells CBPI—cytokinesis-block proliferation index; MN +CD71 RET—frequency of micronucleated +CD71 reticulocytes (per 1000 +CD71 reticulocytes); MN RET—micronucleus assay in reticulocytes; PBL—peripheral blood lymphocytes; * Significantly different from the within company controls; £ Significantly different from the outwith company controls; ¥ Significantly different from the total controls.
Figure 2Levels of (A) malondialdehyde (MDA) and (B) of 8-hydroxydeoxyguanosine (8-OHdG) in pre- (in blue) and post-shift (in red) urine samples from groups of workers that were exposed to Cr(VI) and controls. * Extreme values; o outliers.
Correlation between the effect biomarkers considering the data from all the participants.
| MN PBL | MN RET | Comet—Tail Intensity | MDA Pre-Shift | MDA Post-Shift | 8-OHdG Pre-Shift | 8-OHdG Post-Shift | ||
|---|---|---|---|---|---|---|---|---|
| MN PBL | n | 247 |
| 307 | 162 | 207 | 162 | |
| Corr. Coef | −0.143 |
| 0.042 | 0.070 | 0.090 | 0.022 | ||
|
| 0.024 |
| 0.547 | 0.376 | 0.197 | 0.786 | ||
| MN RET | n | 112 | 182 | 137 | 182 | 137 | ||
| Corr. Coef | 0.078 | −0.020 | 0.080 | −0.069 | 0.096 | |||
|
| 0.414 | 0.788 | 0.353 | 0.358 | 0.264 | |||
| Comet—tail intensity | n | 44 | 36 | 44 | 36 | |||
| Corr. Coef | −0.105 | −0.025 | −0.058 | 0.077 | ||||
|
| 0.499 | 0.885 | 0.710 | 0.653 | ||||
| MDA pre-shift | n |
|
| 228 | ||||
| Corr. Coef |
|
| 0.114 | |||||
|
|
|
| 0.086 | |||||
| MDA post-shift | n |
|
| |||||
| Corr. Coef |
|
| ||||||
|
|
|
| ||||||
| 8-OHdG pre-shift | n |
| ||||||
| Corr. Coef |
| |||||||
|
|
| |||||||
| 8-OHdG post-shift | n | |||||||
| Corr. Coef | ||||||||
|
|
Strength of correlation according to the correlation coefficient (corr. Coef.) value: light orange cell: 0.1 ≤ 0.2 = poor; orange cell: 0.2 ≤ 0.5 = fair; light green: 0.5 ≤ 0.7 = moderate; light grey cell: tested, but no significant correlation found. MDA—malondialdehyde; 8-OHdG—8-hydroxy-2′-deoxyguanosine; MN PBL—frequency of micronucleated binucleated cells per 1000 binucleated cells; MN RET—frequency of micronucleated reticulocytes per 1000 +CD71 reticulocytes.
Results of the correlation analysis between exposure and effect biomarkers.
| MN PBL | MN RET | Comet—Tail Intensity | MDA Pre-Shift | MDA Post-Shift | 8-OHdG Pre-Shift | 8-OHdG Post-Shift | ||
|---|---|---|---|---|---|---|---|---|
| Cr in plasma | n |
| 251 |
| 284 | 217 | 284 | 217 |
| Corr. Coef |
| −0.038 |
| 0.068 | −0.115 | −0.033 | −0.099 | |
|
|
| 0.552 |
| 0.256 | 0.091 | 0.576 | 0.147 | |
| Cr in red blood cells | n | 279 | 251 |
| 284 | 217 |
| 217 |
| Corr. Coef | 0.086 | −0.098 |
| 0.027 | −0.020 |
| −0.063 | |
|
| 0.153 | 0.122 |
| 0.653 | 0.771 |
| 0.357 | |
| U-Cr (pre-shift) | n |
| 233 |
| 283 | 219 | 283 | 219 |
| Corr. Coef |
| 0.023 |
| 0.029 | −0.074 | 0.067 | −0.008 | |
|
|
| 0.723 |
| 0.626 | 0.273 | 0.258 | 0.910 | |
| U-Cr (post-shift) | n |
| 224 |
| 277 |
| 277 |
|
| Corr. Coef |
| −0.009 |
| 0.079 |
| 0.072 |
| |
|
|
| 0.888 |
| 0.190 |
| 0.234 |
|
Strength of correlation according to the correlation coefficient (corr. Coef.) value: 0.1 ≤ 0.2 = poor; 0.2 ≤ 0.5 = fair; 0.5 ≤ 0.7 = moderate. U-Cr—concentration of Cr in urine; MDA—malondialdehyde; 8-OHdG—8-hydroxy-2′-deoxyguanosine; MN PBL—frequency of micronucleated binucleated cells per 1000 binucleated cells; MN RET—frequency of micronucleated reticulocytes per 1000 +CD71 reticulocytes.